Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epinephrine + albuterol is a combination of two adrenergic agonists, both classified as bronchodilators. Epinephrine is a non-selective adrenergic agonist that stimulates alpha and beta-adrenergic receptors, leading to bronchodilation, increased heart rate, and vasoconstriction. It is primarily used for emergency treatment of anaphylaxis and severe asthma exacerbations[6][8]. Albuterol (also known as salbutamol) is a selective beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle to relieve bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD)[2][10]. The combination may theoretically provide additive or synergistic bronchodilation but also increases the risk of cardiovascular side effects due to overlapping mechanisms[4][5]. This specific combination does not have an established brand name or widespread clinical use; it may be considered in special circumstances under close medical supervision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epinephrine + albuterol.